Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.
Japan: A recent study published in Diabetes Therapy has shown the efficacy of luseogliflozin (SGLT2 inhibitor) over DPP-4 inhibitors in the mid/long-term, irrespective of BMI or age.The study revealed.
1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse cardiac events (MACE) in veterans with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). 2. The addition of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was not associated with a primary reduction in major adverse cardiac
Study provides real-world assurance that SGLT2 inhibitors have no added risk of fracture in patients with mainly mild kidney disease after a year of use. But follow-up was short, say experts.